- Home
- RXO vs HCM Comparison
RXO vs HCM Comparison
Compare RXO & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RXO | HCM |
|---|---|---|
| Founded | 2022 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RXO | HCM |
|---|---|---|
| Price | $13.69 | $14.70 |
| Analyst Decision | Hold | Sell |
| Analyst Count | 15 | 1 |
| Target Price | ★ $16.25 | $13.75 |
| AVG Volume (30 Days) | ★ 2.1M | 38.6K |
| Earning Date | 02-06-2026 | 08-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.53 |
| Revenue | ★ $5,940,000,000.00 | $602,197,000.00 |
| Revenue This Year | $28.02 | N/A |
| Revenue Next Year | $3.31 | $15.54 |
| P/E Ratio | ★ N/A | $5.31 |
| Revenue Growth | ★ 53.85 | N/A |
| 52 Week Low | $10.43 | $11.51 |
| 52 Week High | $26.92 | $19.50 |
Technical Indicators
Market Signals| Indicator | RXO | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 50.49 | 63.54 |
| Support Level | $12.45 | $13.20 |
| Resistance Level | $14.65 | $15.00 |
| Average True Range (ATR) | 0.60 | 0.38 |
| MACD | 0.11 | 0.19 |
| Stochastic Oscillator | 58.62 | 85.56 |
Price Performance
Historical ComparisonAbout RXO RXO Inc.
RXO Inc is a brokered transportation platform defined by cutting-edge technology and a nimble, asset-light business model, with the component being core truck brokerage business. Its operations also include three asset-light, brokered transportation services, all of which complement its truck brokerage business: managed transportation, last mile and freight forwarding. The company operates into one reportable segment. The operates within the transportation industry and in the same geography North America.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.